DRREDDY
Dr. Reddy’s Laboratories Limited (drreddy) Launches First-to-market Bosutinib Tablets 400mg in the U.S.
Dr. Reddy’s Laboratories Limited (DRREDDY) announces the first-to-market launch of Bosutinib Tablets 400mg in the U.S., expanding its oncology portfolio.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers.
Strategic Collaboration
Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product. Milan Kalawadia, CEO – North America, Dr. Reddy’s Laboratories, Inc. said: “This launch demonstrates our commitment to strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable.”
Market Potential
The Bosulif® brand (400mg) had U.S. sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data. This launch positions Dr. Reddy’s as a leader in providing affordable oncology treatments, ensuring critical therapies are accessible to patients in need.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock gains 0.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited Q2fy27 Results Update: Double-digit Growth, Strong Financials
Dr. Reddy’s Laboratories Limited DRREDDY reports double-digit Q2FY27 growth, with ₹8,671 Cr revenue and 20.6% EBITDA margin.
Dr. Reddy’s Laboratories Limited (DRREDDY) showcased robust financial performance for Q2FY27, as per consolidated financial statements under IFRS. The company reported a revenue of ₹8,671 Cr, marking a 1.5% year-on-year growth. The EBITDA margin stood at 20.6%, reflecting consistent double-digit base business growth. The company’s progress across strategic priorities highlights its commitment to innovation and market expansion.
Financial Highlights
The financial highlights for Q2FY27 include a reported EBITDA of ₹1,783 Cr, a 24% year-on-year increase. The PBT reached ₹1,228 Cr, up 33% YoY, and PAT stood at ₹925 Cr, with a 36% YoY growth. Notably, the RoCE was annualized at 9.5%, and the net cash surplus stood at ₹2,502 Cr.
Strategic Initiatives
Dr. Reddy’s Laboratories Limited has made significant strides in its strategic initiatives. The company partnered with Takeda for India’s first CDSCO approved dengue vaccine, QDENGA, set to launch in private markets in H1 2027. Additionally, collaborations with Gilead Sciences and GARDP Foundation have expanded its global footprint.
The company also secured approval for rituximab biosimilar from the USFDA and launched nivolumab biosimilar in India. Furthermore, generic semaglutide has been approved in 10 countries across Latin America, Africa & the Middle East, as well as Canada & India.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited (NSE: Drreddy) Receives DCGI Approval for Zytorvi® in Advanced Esophageal Squamous Cell Carcinoma
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) announced DCGI approval for Zytorvi® in advanced esophageal squamous cell carcinoma.
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) announced today that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi® (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This marks the second approved indication for Zytorvi® in India, expanding its use beyond its initial approval in nasopharyngeal carcinoma (NPC).
Expanding Access to Immunotherapy
Through this approval, Dr. Reddy’s Laboratories Ltd. aims to expand access to first-line immunotherapy for appropriate patients with advanced ESCC in India. The approval is supported by the results from the Phase 3 JUPITER-06 trial, which demonstrated a 42% reduction in the risk of disease or death compared with chemotherapy alone.
Significant Market Opportunity
In 2024, esophageal cancer was the fourth leading cause of cancer-related death in India, accounting for approximately 8.1% of all cancer deaths. ESCC, the predominant subtype, accounts for approximately 80% of all esophageal cancer cases in India. With this approval, Dr. Reddy’s Laboratories Ltd. is taking a significant step in addressing this critical need.
M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said: “Following the approval of Zytorvi® in nasopharyngeal carcinoma, this second indication marks an important step in extending the reach of immunotherapy to patients with advanced esophageal squamous cell carcinoma. It gives physicians an additional first-line treatment option for appropriate patients. As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited (drreddy) Q2fy27 Results: Earnings and Revenue Insights
Dr. Reddy’s Laboratories Limited (DRREDDY) to announce Q2FY27 results on October 23rd, focusing on earnings and revenue insights.
Dr. Reddy’s Laboratories Limited (DRREDDY) is set to release its financial results for the quarter and six months ended September 30th, 2026 on Friday, October 23rd. The announcement will focus on key earnings and revenue insights. The company will hold an earnings call at 19:30 PM IST / 10:00 AM ET to discuss the financial performance. The call will be hosted by the company and can be accessed via the provided link for registration. This event marks a significant moment for investors and stakeholders to gain a deeper understanding of the company’s financial health and future prospects.
Financial Performance Overview
The upcoming release will provide detailed insights into Dr. Reddy’s Laboratories’ financial performance for Q2FY27. Notably, the company’s earnings and revenue are expected to reflect its strategic initiatives and market dynamics. The earnings call will offer a platform for management to elaborate on these aspects, highlighting key metrics and future growth strategies.
Investor Engagement
Investors are encouraged to participate in the earnings call to gain direct insights from the company’s leadership. The call will be available in audio format, with a transcript also accessible on the company’s website. This engagement is crucial for understanding the company’s current standing and future trajectory in the pharmaceutical sector.
As Dr. Reddy’s Laboratories Limited prepares to unveil its Q2FY27 results, the focus remains on delivering valuable financial insights that will guide stakeholders in making informed decisions.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. falls 10.4% over three months and has not found a floor yet. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock gains 5.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -10.4% in three months on 11.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
-
Consumer Defensive3 days agoLt Foods Limited Launches Campaign for Rozana with Celebrity Chef Ranveer Brar
-
RAYMONDREL3 days agoRaymond Realty Limited (raymondrel) Secures ₹210 Crore Investment for Ten X Realty West
-
Auto Parts3 days agoSona BLW Precision Forgings Limited Q2 FY27 Results: Record Revenue, Ebitda, and PAT
-
Basic Materials3 days agoChemcon Speciality Chemicals Limited Q2 FY27: Revenue Up 22%, PAT Surges 31%
-
Auto Parts3 days agoLumax Industries Limited (lumaxind) Q2fy27: Revenue Up 33%, PAT Surges 46%
-
Conglomerates3 days agoDcm Shriram Limited (dcmshriram) Q2 FY27: 22% Revenue Growth at ₹3,977 Crore
-
BRIGHOTEL3 days agoBrigade Hotel Ventures Limited (brighotel) Q2 FY27: PAT More Than Doubles
-
KFINTECH3 days agoKfin Technologies Limited Q2fy27: Strong Performance Driven by Broad-based Revenue Growth and Margin Expansion